Friday, May 27, 2016 12:52:11 PM
Even after all these years of practicing technical analysis, it amazes me how well support and resistance price levels function.
The current support, in the 1.50 to 1.60 range has been holding since May 5th, but it's getting long-in-the-tooth. On the bar chart it's taking the form of a descending triangle, a classic text-book chart pattern. In theory it could remain within this pattern until early July but that's not likely. A more probable scenario would see the stock breaking support ( close < 1.45) by early June.
The pattern is interesting because of its ability to project the extent of the next move when it occurs. Using the so-called half-mast rule it would project a price decline on the order of 55% from the price of 1.70. or about 75 cents. This is wonderfully consistent with other targeting methods.
Only a major bullish event can save the bulls now. Of course if one were to sell now and then re purchase lower, it would start the long-term capital gains clock ticking again. You would need to hold for minimum 12 months to get the lower tax rate on a gain. But with NNVC history, a 12 month hold is the least of your worries.
I become interested at 50 cents.
Hope you find my analysis to be of some value.
trendliner.
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City • GlobeNewswire Inc. • 05/04/2023 10:45:00 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM